Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD
Open Access
- 20 February 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (8), 568-581
- https://doi.org/10.1182/blood.2019001696
Abstract
Gastrointestinal (GI) tract involvement is the major cause of morbidity and mortality in acute graft-versus-host disease (GVHD), and pathological damage is largely attributable to inflammatory cytokine production. Recently, granulocyte-macrophage colony stimulating factor (GM-CSF) has been identified as a cytokine that mediates inflammation in the GI tract, but the transcriptional program that governs GM-CSF production and the mechanism by which GM-CSF links adaptive to innate immunity within this tissue site have not been defined. In the current study, we identified Bhlhe40 as a key transcriptional regulator that governs GM-CSF production by CD4+ T cells and mediates pathological damage in the GI tract during GVHD. In addition, we observed that GM-CSF was not regulated by either interleukin 6 (IL-6) or IL-23, which are both potent inducers of GVHD-induced colonic pathology, indicating that GM-CSF constitutes a nonredundant inflammatory pathway in the GI tract. Mechanistically, GM-CSF had no adverse effect on regulatory T-cell reconstitution, but linked adaptive to innate immunity by enhancing the activation of donor-derived dendritic cells in the colon and subsequent accumulation of these cells in the mLNs. In addition, GM-CSF promoted indirect alloantigen presentation, resulting in the accumulation of donor-derived T cells with a proinflammatory cytokine phenotype in the colon. Thus, Bhlhe40+ GM-CSF+ CD4+ T cells constitute a colitogenic T-cell population that promotes indirect alloantigen presentation and pathological damage within the GI tract, positioning GM-CSF as a key regulator of GVHD in the colon and a potential therapeutic target for amelioration of this disease.Keywords
This publication has 62 references indexed in Scilit:
- Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database AnalysisTransplantation and Cellular Therapy, 2019
- Acute graft-versus-host disease of the gut: considerations for the gastroenterologistNature Reviews Gastroenterology & Hepatology, 2017
- Pathogenesis of acute graft‐versus‐host disease: from intestinal microbiota alterations to donor T cell activationBritish Journal of Haematology, 2016
- Advances in understanding the pathogenesis of graft‐versus‐host diseaseBritish Journal of Haematology, 2016
- Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host diseaseThe Journal of Experimental Medicine, 2015
- Graft-versus-host disease is enhanced by extracellular ATP activating P2X7RNature Medicine, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Graft-versus-host diseaseNature Reviews Immunology, 2007
- Immunobiology of Allogeneic Hematopoietic Stem Cell TransplantationAnnual Review of Immunology, 2007
- The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantationBlood, 2000